- Report
- June 2026
- 200 Pages
Global
From €2682EUR$2,990USD£2,295GBP
- Report
- August 2026
- 382 Pages
Global
From €5248EUR$5,850USD£4,491GBP
- Report
- January 2026
- 181 Pages
Global
From €3180EUR$3,545USD£2,721GBP
€3534EUR$3,939USD£3,024GBP
- Report
- August 2026
- 375 Pages
Global
From €5248EUR$5,850USD£4,491GBP
- Report
- February 2026
- 162 Pages
China
From €4351EUR$4,850USD£3,723GBP
- Book
- April 2026
North America
- Book
- September 2025
United States
- Book
- July 2025
North America
- Book
- May 2025
North America
- Book
- December 2024
United States
- Book
- December 2024
United States
- Book
- July 2024
United States
- Book
- November 2022
North America

The psychopharmacology market is a subset of the mental health industry that focuses on the use of drugs to treat mental health disorders. It is a rapidly growing field, with a wide range of medications available to treat a variety of conditions. These medications are used to treat depression, anxiety, bipolar disorder, schizophrenia, and other mental health disorders. The medications are prescribed by psychiatrists and other mental health professionals, and are often used in combination with psychotherapy and other treatments.
The psychopharmacology market is highly competitive, with a number of companies offering a variety of medications. Some of the major players in the market include Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca, and Johnson & Johnson. These companies are constantly researching and developing new medications to treat mental health disorders, as well as providing support and education to mental health professionals. Show Less Read more